Advanced

Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference

Berntorp, Erik LU ; Shapiro, A ; Astermark, Jan LU ; Blanchette, V. S ; Collins, P. W ; Dimichele, D ; Escuriola, C ; Hay, C. R. M ; Hoots, W. K and Leissinger, C. A , et al. (2006) In Haemophilia 12. p.41281-41281
Abstract
Participants in an international conference on the management of haemophilia patients with inhibitors developed a jointly authored summary of the findings and conclusions of the conference. Current knowledge of the genetic and immunologic mechanisms underlying inhibitor development was briefly summarized. Concerning the purported treatment-related risk factors, conference participants commented on the limitations of the available evidence and the need for more rigorous prospective research in a fully genotyped population. Other clinical considerations discussed included the unproved utility of routine surveillance, the need for assay standardization, the management of acute bleeding and approaches to joint disease prophylaxis and immune... (More)
Participants in an international conference on the management of haemophilia patients with inhibitors developed a jointly authored summary of the findings and conclusions of the conference. Current knowledge of the genetic and immunologic mechanisms underlying inhibitor development was briefly summarized. Concerning the purported treatment-related risk factors, conference participants commented on the limitations of the available evidence and the need for more rigorous prospective research in a fully genotyped population. Other clinical considerations discussed included the unproved utility of routine surveillance, the need for assay standardization, the management of acute bleeding and approaches to joint disease prophylaxis and immune tolerance induction (ITI). A number of issues were identified as needing further investigation in larger prospective studies, ideally through international cooperation. Such studies should enrol cohorts that have been scrupulously defined in terms of mutation status and treatment exposure. Finally, conference participants urged their colleagues to participate in the currently ongoing international trials of ITI. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
inhibitors, haemophilia, diagnosis, treatment, guidelines
in
Haemophilia
volume
12
pages
41281 - 41281
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000242603200001
  • scopus:33750988816
  • pmid:17123387
ISSN
1351-8216
DOI
10.1111/j.1365-2516.2006.01359.x
language
English
LU publication?
yes
id
406bb2e3-c89a-4c6a-925b-558f108dc6ab (old id 683702)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17123387&dopt=Abstract
date added to LUP
2016-04-01 12:31:20
date last changed
2020-03-11 02:59:42
@misc{406bb2e3-c89a-4c6a-925b-558f108dc6ab,
  abstract     = {Participants in an international conference on the management of haemophilia patients with inhibitors developed a jointly authored summary of the findings and conclusions of the conference. Current knowledge of the genetic and immunologic mechanisms underlying inhibitor development was briefly summarized. Concerning the purported treatment-related risk factors, conference participants commented on the limitations of the available evidence and the need for more rigorous prospective research in a fully genotyped population. Other clinical considerations discussed included the unproved utility of routine surveillance, the need for assay standardization, the management of acute bleeding and approaches to joint disease prophylaxis and immune tolerance induction (ITI). A number of issues were identified as needing further investigation in larger prospective studies, ideally through international cooperation. Such studies should enrol cohorts that have been scrupulously defined in terms of mutation status and treatment exposure. Finally, conference participants urged their colleagues to participate in the currently ongoing international trials of ITI.},
  author       = {Berntorp, Erik and Shapiro, A and Astermark, Jan and Blanchette, V. S and Collins, P. W and Dimichele, D and Escuriola, C and Hay, C. R. M and Hoots, W. K and Leissinger, C. A and Negrier, C and Oldenburg, J and Peerlinck, K and Reding, M. T and Hart, C},
  issn         = {1351-8216},
  language     = {eng},
  pages        = {41281--41281},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference},
  url          = {http://dx.doi.org/10.1111/j.1365-2516.2006.01359.x},
  doi          = {10.1111/j.1365-2516.2006.01359.x},
  volume       = {12},
  year         = {2006},
}